Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Outlook Therapeutics, Inc. (NASDAQ:OTLK) will release its third quarter earnings report before the opening bell on Friday, Aug. 14.
Analysts expect the Iselin, New Jersey-based company to report a quarterly loss of 8 cents per share, versus a loss of 44 cents per share in the year-ago period. The consensus estimate for OTLK’s quarterly revenue is $966.67 thousand. It reported $1.5 million last year, according to Benzinga Pro.
On Aug. 12, Outlook Therapeutics announced the pricing of $55.0 million public offering of common stock and warrants.
Shares of Outlook Therapeutics fell 19.2% to close at $0.89 on Thursday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
- HC Wainwright & Co. analyst Douglas Tsao maintained a Neutral rating and raised the price target from $0.5 to $1.6 on July 27, 2026. This analyst has an accuracy rate of 74%.
- BTIG analyst Julian Harrison upgraded the stock from Neutral to Buy with a price target of $4 on July 27, 2026. This analyst has an accuracy rate of 82%.
- Ascendiant Capital analyst Edward Woo maintained a Buy rating and raised the price target from $6 to $10 on June 11, 2026. This analyst has an accuracy rate of 54%.
- Chardan Capital analyst Daniil Gataulin maintained the stock with a Neutral rating with a price target of $1 on Feb. 18, 2026. This analyst has an accuracy rate of 80%.
- Guggenheim analyst Eddie Hickman downgraded the stock from Buy to Neutral on Aug. 29, 2025. This analyst has an accuracy rate of 74%
Considering buying OTLK stock? Here’s what analysts think:
Photo via Shutterstock